It’s About Time
A rare convergence of breakthroughs in biotechnology and computational biology is creating one of the most compelling investment opportunities of our generation. Longevity Angels gives accredited investors curated, early-stage access to the companies leading this transformation.
Open to accredited investors. Nothing on this page is an offer to sell or a solicitation of an offer to buy any security.
Investors who take the biology seriously.
Longevity Angels is a group of investors supporting early-stage biotechnology companies developing therapies that target the underlying biology of aging.
Our approach emphasizes thoughtful deal selection and reasonable minimum investment sizes, enabling accredited investors of all levels to participate.
The hard part was never finding the science. It was being allowed in.
Private rounds in this sector are sized for institutions. A single allocation routinely starts in the six figures and beyond. This quietly makes early-stage biotech a place you can only participate in if you can consistently deploy large amounts of capital.
Not for lack of conviction or understanding, but most individual investors never clear that bar.
We size our minimums for the investor, not the cap table.
A position you can actually diversify
Participating in an array of investments yields better results than concentrating your capital on a single deal. Approaching each company at a level that you feel comfortable with makes that possible.
The same terms, the same room
A smaller commitment does not buy a smaller version of the deal. Every investor in an SPV receives the same diligence materials, the same negotiated terms, and the same invitation to meet the company's executives.
No obligation, ever
There is no commitment to participate in any particular offering, and no penalty for passing. You look at what we send, and you decide. The choice is always yours to make.
Longevity Angels' offerings begin here and vary deal by deal. This allows you to align your investments with your principles, across a variety of offerings.
Allocation is finite. An SPV can only invest what a company has allocated to it, and is generally limited to 100 beneficial owners under the Investment Company Act. Where a deal is oversubscribed, allocations are managed deliberately rather than filled first-come.
Aging is no longer the backdrop. It is the primary target.
For most of medicine's history, aging itself was not treated directly. Cheap sequencing, functional genomics, and computational biology have now made the underlying processes measurable. Once something is measurable, it can be aimed at. These are the areas our diligence keeps returning to.
Cellular Reprogramming
Partial expression of reprogramming factors to reset a cell's epigenetic state without erasing its identity. The work has moved from lab rat proof-of-concept toward tissue-specific delivery and control.
Senescent Cell Clearance
Senescent cells stop dividing but do not die, accumulating and secreting inflammatory signals into the tissue around them. Selectively removing them, or silencing what they secrete, is among the more clinically advanced approaches in the field.
Consumer Healthspan
Longevity’s reach spans beyond just pharmaceuticals. Those rebuilding everyday products (oral care, nutrition, supplements) around better science inherit a market that already exists: the customer changes brand, not behaviour. That is a rare place to start from.
Immune Resilience
The thymus involutes early in life and the adaptive immune system narrows with it. Regenerating thymic tissue and restoring T-cell diversity has implications well beyond infection.
Fibrosis
Tissues stiffen as their extracellular scaffolding accumulates damage and crosslinks. Breaking those crosslinks, or reversing fibrotic remodelling, addresses a failure mode common to nearly every organ.
Measurement & Computation
Epigenetic clocks, proteomic and multi-omic aging markers, and the models built on top of them. Nothing in this field becomes a real clinical program until the endpoint can be measured in less than a lifetime.
Areas of active interest, described generally. This is not a portfolio listing, and nothing above refers to any specific company, offering or transaction.
What you know at the moment you commit.
The distinction between a fund and an SPV is more about timing than structure. One asks you to choose a manager; the other asks you to choose a company.
A traditional venture fund
- You commit capital to a portfolio that has not been selected yet.
- You underwrite the manager's judgement in advance and accept the portfolio they choose to build.
- Capital calls arrive on the fund's schedule, not yours.
- Diversification is handled for you, automatically.
A Longevity Angels SPV
- You see the specific company, the diligence, and the terms before you decide anything.
- You choose which companies to back and how much to commit to each.
- No capital calls you don’t see coming, and no obligation to join anything you do not want to.
- Diversification is something you build yourself, across deals, over time.
The honest tradeoff: a fund diversifies you automatically. With SPVs, diversification is something you build deliberately by participating across a number of deals. Concentrating heavily into one or two companies is a materially different risk profile than a portfolio, and it is worth being intentional about that.
Six things that happen, in order.
From the first look at a company through to your K-1, every step is documented, administered and visible to you.
Curated Deal Flow
The Longevity Angels team carefully curates deals, ensuring they provide access to companies with revolutionary technology and promising exit opportunities. Each portfolio company undergoes a thorough evaluation process before being presented to investors, allowing only a select few to receive funding. This selectivity is intentional. Longevity Angels’ portfolio companies are revolutionizing the ways we age, in real time.
Custom SPVs Built for Our Investors
Longevity Angels structures each deal through a Special Purpose Vehicle (SPV); No blind-pool funds, full transparency. Our deal-by-deal structure gives investors full discretion over the companies they back and the amount they invest. Investors have direct access to executives at Longevity Angels’ portfolio companies. Additionally, the terms of each deal are carefully negotiated to ensure clients receive the highest potential return on investment.
Full Transparency and Direct Access
We believe trust is built through transparency. Longevity Angels provides full access to all available diligence materials for each offering. Investors are invited to meet with executives and ask any questions they may have. The investment experience is far greater than writing a check, your confidence in the company is our priority.
Seamless Administration Through Sydecar
Each Longevity Angels offering is structured through Sydecar, a purpose-built venture investing platform. Each step of the investment process from subscription documents to wiring instructions is handled on Sydecar. Investors can view committed capital, investment documents, and compliance filings across all Longevity Angels deals through one intuitive dashboard.
Annual Reporting and Tax Documentation
Longevity Angels manages all annual reporting on behalf of each SPV, including K-1s, year-end statements, and any required regulatory filings. Tax documents are sent through Sydecar and our team is available to field any questions regarding tax and compliance.
Ongoing Access to New Opportunities
An investment with Longevity Angels is far more than a transaction. Once you’ve invested, you join a community of passionate investors with strong belief in the future of longevity. Past investors receive early access to new deals; granting them a headstart in the investment process. There’s no obligation to invest in every offering, but you’ll always have a seat at the table.
The things people ask first.
What is an SPV, and how is it different from investing in a fund?
An SPV (special purpose vehicle) is a company formed for the sole purpose of making one investment. When Longevity Angels backs a company, we form an SPV for that specific deal. Investors subscribe to the SPV, the SPV buys shares in the company, and in the event of an exit, proceeds flow back through the SPV to the people who funded it.
The difference from a traditional venture fund is what you know at the moment you commit.
What is an accredited investor?
Accredited investor status is defined by the SEC in Rule 501(a) of Regulation D. Most individuals qualify either on income (more than $200,000 individually or $300,000 jointly in each of the two most recent years) or on net worth of more than $1 million, excluding the value of a primary residence. Holding a Series 7, 65 or 82 licence in good standing also qualifies you.
Are there minimum or maximum investment sizes?
The minimum is typically $5,000. It varies deal by deal, and the minimum that applies to any particular offering is stated in that offering's documents. There is no fixed maximum, but allocation is finite. An SPV can only invest what the company has allocated to it, so larger commitments are always subject to availability.
What stage companies do you invest in?
Early stage companies, generally pre-seed through Series A. These are companies building something that does not exist yet, most of the time before revenue and occasionally before a product. We look at scientific milestones including target validation, candidate nomination, IND, and clinical readouts to determine the growth potential of companies.
Can I invest through an LLC, trust, or IRA?
Generally yes, and many investors do; The requirements differ by structure. If you intend to invest via any of the above, please let us know in the interest form and we will reach out directly to discuss structure options.
The renaissance for Longevity Technology is here
Join the community of investors funding the next generation of Longevity Biotech.
Longevity Angels is not a registered broker-dealer, investment adviser or investment company. Nothing on this page is an offer to sell or a solicitation of an offer to buy any security. Any offering is made only to accredited investors through definitive offering documents delivered via Sydecar, which govern in all respects. Investing in early-stage private companies is speculative, illiquid and involves a high degree of risk.